| |
|
|
|
Xtalks, Online
2025-05-12
Clinical trial start-up delays are a persistent challenge in oncology drug development, often leading to increased oversight costs, delayed patient enrollment and prolonged time to market.
Inefficiencies in start-up time can add months to trial timelines, impacting both financial and competitive positioning. In this webinar, the expert speakers will discuss the key factors contributing to trial start-up inefficiencies and explore data-driven strategies to mitigate these delays.
By initiating key operational activities ahead of regulatory submission, sponsors can shorten the time between the FDA’s “May Proceed” letter and site activation—saving up to over four months in start-up timelines. They will cover the following key topics:
Common bottlenecks in clinical trial start-up and their financial impact
Importance of early site engagement and balancing site selection between community and research institutions
Best practices for vendor identification and contract execution before investigational new drug (IND) submission
Role of preemptive regulatory document preparation in streamlining site activation
Case studies highlighting how a proactive approach has led to faster enrollment and cost savings
With a growing emphasis on efficiency in clinical trials, it is essential for sponsors to rethink their approach to trial start-up. This session will provide actionable insights to help optimize early-stage trial operations, reduce delays and accelerate patient enrollment.
Join this webinar to learn how proactive planning can significantly reduce clinical trial start-up timelines and enhance overall study efficiency.
Keywords: Clinical Trials, Clinical Trial, Drug Development, Clinical Research, CRO, Oncology, Patient Recruitment, Clinical Operations, Study Start-Up, Sponsors, Decentralized Clinical Trials, DCT
|
|
|
|
|
|
|
|
Organized by:
|
|
Xtalks |
|
|
Invited Speakers:
|
|
Jennifer Keppler, Vice President, Translational Medicine, Translational Drug Development (TD2)
Nick Conde, Translational Program Manager, Translational Drug Development (TD2)
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
2025-05-12
|
|
|
|
|
|
|
|
Registration:
|
|
Free Registration
|
|
|
E-mail:
|
|
tristan@xtalks.com
|
|
|
|
|
|
|
|
|
|
|
|
|